# Administrative Supplement: Interim Funding for Emory Lung Cancer SPORE

> **NIH NIH P50** · EMORY UNIVERSITY · 2024 · $896,274

## Abstract

OVERVIEW SUMMARY/ABSTRACT
Lung cancer is the leading cause of cancer-related deaths, with more than 1.6 million deaths/year globally. It is
often diagnosed at an advanced stage and is associated with poor outcomes for the majority of patients. This
application for a lung cancer SPORE award from Emory University brings together an outstanding and multi-
team of oncologists, immunologists, drug discovery experts, and translational researchers dedicated to lung
cancer research to address critical questions that will improve the outcome for patients with this lethal disease.
Our proposed program will have significant impact in two crucial areas of lung cancer management: enhancing
the efficacy of immunotherapy and overcoming treatment resistance through the development of novel
molecularly targeted agents. Through strong teamwork carried out by this highly collaborative team of dedicated
investigators, and building on exciting data published in leading journals by our group since our previous SPORE
application, this revised submission aims to achieve substantial improvements in the management of patients
with non-small cell lung cancer (NSCLC), through three overall Specific Aims: Aim 1: To evaluate stem-like T
cells and improve efficacy of checkpoint inhibitors in NSCLC (Project 1); Aim 2: To target MERTK to
improve outcomes for EGFR-mutated NSCLC (Project 2); and Aim 3: To target Bax signaling to overcome
treatment resistance in NSCLC (Project 3). The Emory Lung Cancer SPORE program will be supported by
close interaction with the Administrative Core (Core 1), Pathology Core (Core 2) and the Biostatistics and
Biomedical Informatics Core (Core 3), and will conduct Career Enhancement and Developmental Research
Programs (CEP and DRP). The SPORE program will benefit from regular advice and recommendations from
External and Internal Advisory Board members regarding its progress and direction. Our program will receive
strong institutional support including modern research space, excellent shared resources, and a significant level
of matching funds (totaling $2.25M) from the Winship Cancer Institute of Emory University (an NCI-designated
Comprehensive Cancer Center), Emory University Woodruff Health Sciences Center, Emory Healthcare System,
Emory School of Medicine, and the Department of Hematology and Medical Oncology. Through team-driven
innovative research efforts in immunotherapies and molecularly targeted therapeutics, we are confident that this
SPORE program, in collaboration with other lung cancer SPORE sites, will have a major positive impact on the
management of lung cancer.

## Key facts

- **NIH application ID:** 11193012
- **Project number:** 3P50CA217691-05S1
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** Haian Fu
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $896,274
- **Award type:** 3
- **Project period:** 2019-07-10 → 2025-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11193012

## Citation

> US National Institutes of Health, RePORTER application 11193012, Administrative Supplement: Interim Funding for Emory Lung Cancer SPORE (3P50CA217691-05S1). Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/grant/nih/11193012. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*